CK Life Sciences International (Holdings), Inc. (HK:0775) has released an update.
CK Life Sciences International (Holdings), Inc. has completed a strategic transaction involving the sale of its subsidiary’s shares and a loan agreement to facilitate the merger of WEX with a Nasdaq-listed entity. This deal, worth US$100 million and a loan of US$19.5 million, aims to expedite the development and market entry of WEX’s leading product, Halneuron®, by leveraging the purchaser’s expertise and access to U.S. capital markets. The transactions are considered fair and in the interest of the company and its shareholders, enhancing CK Life Sciences’ presence in the biotech industry.
For further insights into HK:0775 stock, check out TipRanks’ Stock Analysis page.
